Abstract

Inactivation of the cyclin-dependent kinase inhibitors p16INK4A and p15INK4B are frequent alterations in neoplasia, often resulting from homozygous deletion or promoter region hypermethylation. We have analyzed both modes of inactivation of p15INK4B and p16INK4A in the major types of adult and pediatric hematological malignancies. Hypermethylation of p15INK4B, without alteration of p16INK4A, was an almost universal finding in adult acute myelogenous leukemia, and occurred very frequently in adult acute lymphocytic leukemia and pediatric acute myelogenous leukemia and acute lymphocytic leukemia. In contrast, neither p15INK4B nor p16INK4A were inactivated in any stage of chronic myelogenous leukemia. Hypermethylation of p16INK4A, often without alterations of p15INK4B, was found in non-Hodgkin's lymphoma and was much more frequent in cases with high-grade than low-grade histology. Enriched normal bone marrow stem cells had no detectable promoter region methylation of these genes, as analyzed by a newly developed PCR method. Remarkably distinct patterns of inactivation of p15INK4B and p16INK4A characterize different types of hematological malignancy, and alterations in these tumor suppressor genes are one of the most common alterations in hematological malignancies.

Keywords

LeukemiaCancer researchChronic myelogenous leukemiaLymphomaAcute lymphocytic leukemiaBone marrowMedicineImmunologyBiologyLymphoblastic Leukemia

Affiliated Institutions

Related Publications

Human tumors studied with genetic markers.

Genetic marker systems have been employed to investigate the origin and development of many human tumors. The type of information already gained with such systems includes the p...

1976 PubMed 12 citations

Publication Info

Year
1997
Type
article
Volume
57
Issue
5
Pages
837-41
Citations
410
Access
Closed

External Links

Citation Metrics

410
OpenAlex

Cite This

James G. Herman, Curt I. Civin, Jean‐Pierre J. Issa et al. (1997). Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies.. PubMed , 57 (5) , 837-41.